Revolution Medicines
RVMD
142 hedge funds and large institutions have $1.74B invested in Revolution Medicines in 2022 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 73 increasing their positions, 22 reducing their positions, and 16 closing their positions.
232% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 22
73% more call options, than puts
Call options by funds: $2.56M | Put options by funds: $1.48M
44% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 16
17% more capital invested
Capital invested by funds: $1.49B → $1.74B (+$254M)
10% more funds holding in top 10
Funds holding in top 10: 10 → 11 (+1)
5% more funds holding
Funds holding: 135 → 142 (+7)
2.22% less ownership
Funds ownership: 102.98% → 100.76% (-2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$44M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$31.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$31.1M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$28.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$26.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$54.4M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$33M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$16.5M |
| 4 |
TP
Thunderbird Partners
London,
United Kingdom
|
-$6.71M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.8M |
RVMD Hedge Fund Activity: Q3 2022 in Review
142 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Revolution Medicines (RVMD) for Q3 2022, worth a combined $1.74B — up 17% from $1.49B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new RVMD positions and 16 closed out — a net gain of 7 holders — while 73 added to existing stakes and 22 trimmed.
The largest buyer was Deerfield Management, adding an estimated $44M. The largest seller was EcoR1 Capital, cutting an estimated $54.4M.
- 142 institutional investors held Revolution Medicines (RVMD) as of Q3 2022, up from 135 in Q2 2022.
- Funds reported $1.74B of Revolution Medicines stock for Q3 2022, up 17% quarter-over-quarter.
- 23 funds opened new Revolution Medicines positions in Q3 2022 and 16 closed out, a net change of +7 holders.
- The largest Revolution Medicines buyer in Q3 2022 was Deerfield Management, an estimated $44M added.
- The largest Revolution Medicines seller in Q3 2022 was EcoR1 Capital, an estimated $54.4M sold.
Based on aggregated 13F filings for Q3 2022.